Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.

Phase 1

• Conditions: Cervical Cancer
• Interventions: Drug: PD-1 antibody

• Registration Number: NCT04368273
• Lead Sponsor: Peking University Third Hospital

Brief Summary

To evaluate the safety and efficacy of anti-PD-1 (toripalimab) combined with cisplatin concurrent IMRT for locally advanced cervical cancer.

Detailed Description

The dose of toripalimab injection (pd-1 antibody) was 240mg/d, d1, i.v. every 14d, totally 4 cycles (56 days)

Concurrent chemoradiotherapy:

Cisplatin 40 mg/m2 i.v., d1, administered once a week; Radiotherapy: pelvic intensity modulated radiotherapy, prescription dose DT: 50.4gy /2Gy/28f;After intraluminal irradiation DT: 30-36 Gy/6Gy/5-6f 2f/w, complete the radiotherapy within 56 days.

Complete at least 4 cycles of concurrent chemoradiotherapy.

Study Timeline

• Status Verified: 2020-04
• Study First Submitted: 2020-04-25
• Study First Submitted QC: 2020-04-27
• Last Update Submitted: 2020-04-27
• Study First Posted: 2020-04-29
• Last Update Posted: 2020-04-29
• Study Start: 2020-05-08
• Primary Completion: 2021-12-31
• Study Completion: 2022-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 30

Inclusion Criteria

1. HPV positive in patients with cervical squamous cell carcinoma confirmed by histopathology
2. Patients with local advanced (2018FIGO staged IB3, IIA -IVA) cervical cancer and had not received any treatment before
3. There are measurable lesions according to the efficacy evaluation criteria for solid tumors (RECIST) version 1.1
4. ECOG score 0-2
5. Expected survival ≥3 months
6. LVEF≥55%
7. Bone marrow function: neutrophils ≥1.5×109/L, platelets ≥100×109/L, hemoglobin ≥90g/L
8. Liver and kidney functions: serum creatinine ≤1.5 times the upper limit of normal value;AST and ALT ≤2.5 times normal upper limit or ≤5 times normal upper limit in the presence of liver metastasis;Total bilirubin ≤1.5 times the upper limit of normal value, or ≤2.5 times the upper limit of normal value in patients with Gilbert's syndrome
9. Thyroid function: normal range
10. Non-lactating patients
11. Sign the informed consent

Read More

Exclusion Criteria

1. Patients with previous PD-1 or PD-L1 treatment

2. Patients with previous abdominal or pelvic radiotherapy

3. Other malignant tumors other than cervical cancer appeared in the past 5 years

4. Immunosuppressive drugs were used within 4 weeks prior to the first study treatment, excluding nasal spray, inhaled or other local glucocorticoids or systemic glucocorticoids in physiological doses (i.e., no more than 10 mg/ day prednisone or equivalent doses of other glucocorticoids)

5. Active, known, or suspected autoimmune disease (congenital or acquired)

   ), such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, thyroiditis, etc. (vitiligo or childhood asthma has been completely relieved, adults without any intervention can be included;Patients with type 1 diabetes with good insulin control can also be enrolled, as can hypothyroidism caused by autoimmune thyroiditis that requires hormone replacement therapy.)

6. Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation

7. Known allergy to any component of the drug

8. Serious medical diseases that are not under control, such as the combination of serious medical diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension,uncontrolled infection, active peptic ulcer

9. Received other experimental drugs or participated in other drugs within 30 days of initial administration clinical research on the purpose of anticancer therapy

10. Severe infection occurred within 4 weeks prior to study treatment, including, but not limited to, hospitalization hospital treatment of infection complications, bacteremia or severe pneumonia

11. Human immunodeficiency virus (HIV) positive

12. Hepatitis B surface antigen (HBsAg) positive, and the peripheral blood hepatitis B virus deoxygenation the titer of ribonucleic acid (HBV-DNA) was detected in subjects ≥1×10<3> IU/mL

13. Hepatitis C virus (HCV) antibody positive or human immunodeficiency virus (HIV) Antibody positive and HCV RNA positive

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
treatment	PD-1 antibody	PD-1 antibody combined CCRT for patients with local advanced cervical cancer.

Primary Outcome Measures

Name	Time	Method
Incidence and severity of acute adverse events	up to 3 months complete treatment	safety evaluation

Secondary Outcome Measures

Name	Time	Method
Objective response rate	3 months later after treatment	efficacy evaluation
Progression-free survival	up to 2 years	efficacy evaluation

Trial Locations

Locations (1)

Peking University 3rd Hospital; 🇨🇳 Beijing, Beijng, China